UB Paderborn / Katalog / Suche / in CDI

Safety and efficacy assessment of plerixafor in patients with multiple myeloma proven or predicted to be poor mobilizers, including assessment of tumor cell mobilization

Bone marrow transplantation (Basingstoke), 2010-01, Vol.45 (1), p.63-68

2010

Volltextzugriff (PDF)

Hematopoietic progenitor cell collection after autologous transplant for multiple myeloma: low platelet count predicts for poor collection and sole use of resulting graft enhances risk of myelodysplasia

Leukemia, 2014-04, Vol.28 (4), p.888-893

2014

Volltextzugriff (PDF)

Cytomegalovirus infection and non‐neutropenic fever after autologous stem cell transplantation: high rates of reactivation in patients with multiple myeloma and lymphoma

British journal of haematology, 2001-01, Vol.112 (1), p.237-241

2001

Volltextzugriff (PDF)

Sweet syndrome in multiple myeloma: a series of six cases

Journal of cutaneous pathology, 2003-04, Vol.30 (4), p.261-264

2003

Volltextzugriff (PDF)

CD34+ Cell Dose Predicts Survival, Posttransplant Morbidity, and Rate of Hematologic Recovery After Allogeneic Marrow Transplants for Hematologic Malignancies

Blood, 1996-10, Vol.88 (8), p.3223-3229

1996

Volltextzugriff (PDF)

Cancer and the microenvironment : Myeloma-osteoclast interactions as a model

Cancer research (Chicago, Ill.), 2004-03, Vol.64 (6), p.2016-2023

2004

Volltextzugriff (PDF)

T cell-depleted bone marrow transplantation and delayed T cell add-back to control acute GVHD and conserve a graft-versus-leukemia effect

Bone marrow transplantation (Basingstoke), 1998-03, Vol.21 (6), p.543-551

1998

Volltextzugriff (PDF)

Inhibitory effects of osteoblasts and increased bone formation on myeloma in novel culture systems and a myelomatous mouse model

Haematologica (Roma), 2006-02, Vol.91 (2), p.192-199

2006

Volltextzugriff (PDF)

DTPACE: An Effective, Novel Combination Chemotherapy With Thalidomide for Previously Treated Patients With Myeloma

Journal of clinical oncology, 2003-07, Vol.21 (14), p.2732-2739

2003

Volltextzugriff (PDF)

Recovery from neutropenia can be predicted by the immature reticulocyte fraction several days before neutrophil recovery in autologous stem cell transplant recipients

Bone marrow transplantation (Basingstoke), 2006-02, Vol.37 (4), p.403-409

2006

Volltextzugriff (PDF)

High-dose cyclophosphamide with or without etoposide for mobilization of peripheral blood progenitor cells in patients with multiple myeloma: efficacy and toxicity

Bone marrow transplantation (Basingstoke), 2004-07, Vol.34 (1), p.69-76

2004

Volltextzugriff (PDF)

Transplantation as salvage therapy for high-risk patients with myeloma in relapse

Bone marrow transplantation (Basingstoke), 2002-12, Vol.30 (12), p.873-878

2002

Volltextzugriff (PDF)

In situ hybridization in HIV research

Microscopy research and technique, 1993-05, Vol.25 (1), p.78-84

1993

Volltextzugriff (PDF)

Hybrid cord blood banks may be advantageous for scientific as well as economic reasons

Cytotherapy (Oxford, England), 2020-05, Vol.22 (5), p.S56-S57

2020

Volltextzugriff (PDF)

Improved Outcome of Allogeneic Transplantation in High-Risk Multiple Myeloma Patients After Nonmyeloablative Conditioning

Journal of clinical oncology, 2002-03, Vol.20 (5), p.1295-1303

Badros, A.

2002

Volltextzugriff (PDF)

Evaluation of methods for preparing and thawing cryopreserved CD34+ and CD34− cell lines for use as reagents in flow cytometry of hematopoietic progenitor cells

Transfusion (Philadelphia, Pa.), 1996-11, Vol.36 (11-12), p.985-988

1996

Volltextzugriff (PDF)

Mobilization of CD34+ cells in elderly patients (≥ 70 years) with multiple myeloma: influence of age, prior therapy, platelet count and mobilization regimen

British journal of haematology, 2003-02, Vol.120 (3), p.413-423

2003

Volltextzugriff (PDF)

Autologous stem cell transplantation followed by consolidation chemotherapy for patients with multiple myeloma

Bone marrow transplantation (Basingstoke), 2006-01, Vol.37 (1), p.65-72

2006

Volltextzugriff (PDF)

SMALL CHANGES, BIG SAVINGS: IMPACT OF HEMATOPOIETIC PROGENITOR CELLS APHERESIS COLLECTION GOALS ON THE CELL THERAPY LAB

Cytotherapy (Oxford, England), 2024-06, Vol.26 (6), p.S123-S124

2024

Volltextzugriff (PDF)

Clonal cytogenetic changes and myeloma relapse after reduced intensity conditioning allogeneic transplantation

Bone marrow transplantation (Basingstoke), 2006-03, Vol.37 (5), p.511-515

2006

Volltextzugriff (PDF)

Retroviral-mediated gene transfer into CD34-enriched human peripheral blood stem cells

Experimental hematology, 1993-04, Vol.21 (4), p.585-591

1993

Volltextzugriff (PDF)

Autotransplantation for advanced lymphoma and Hodgkin's disease followed by post-transplant rituxan/GM-CSF or radiotherapy and consolidation chemotherapy

Bone marrow transplantation (Basingstoke), 2002-02, Vol.29 (4), p.303-312

2002

Volltextzugriff (PDF)

UC blood infection with clinical strains of Mycobacterium tuberculosis : a novel model

Cytotherapy (Oxford, England), 2007, Vol.9 (7), p.647-653

2007

Volltextzugriff (PDF)

High response rate in refractory and poor-risk multiple myeloma after allotransplantation using a nonmyeloablative conditioning regimen and donor lymphocyte infusions

Blood, 2001-05, Vol.97 (9), p.2574-2579

2001

Volltextzugriff (PDF)

Mobilization of peripheral blood stem cells in myeloma with either pegfilgrastim or filgrastim following chemotherapy

Haematologica (Roma), 2008-11, Vol.93 (11), p.1739-1742

2008

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

Safety and efficacy assessment of plerixafor in patients with multiple myeloma proven or predicted to be poor mobilizers, including assessment of tumor cell mobilization

Hematopoietic progenitor cell collection after autologous transplant for multiple myeloma: low platelet count predicts for poor collection and sole use of resulting graft enhances risk of myelodysplasia

Cytomegalovirus infection and non‐neutropenic fever after autologous stem cell transplantation: high rates of reactivation in patients with multiple myeloma and lymphoma

Sweet syndrome in multiple myeloma: a series of six cases

CD34+ Cell Dose Predicts Survival, Posttransplant Morbidity, and Rate of Hematologic Recovery After Allogeneic Marrow Transplants for Hematologic Malignancies

Cancer and the microenvironment : Myeloma-osteoclast interactions as a model

T cell-depleted bone marrow transplantation and delayed T cell add-back to control acute GVHD and conserve a graft-versus-leukemia effect

Inhibitory effects of osteoblasts and increased bone formation on myeloma in novel culture systems and a myelomatous mouse model

DTPACE: An Effective, Novel Combination Chemotherapy With Thalidomide for Previously Treated Patients With Myeloma

Recovery from neutropenia can be predicted by the immature reticulocyte fraction several days before neutrophil recovery in autologous stem cell transplant recipients

High-dose cyclophosphamide with or without etoposide for mobilization of peripheral blood progenitor cells in patients with multiple myeloma: efficacy and toxicity

Transplantation as salvage therapy for high-risk patients with myeloma in relapse

In situ hybridization in HIV research

Hybrid cord blood banks may be advantageous for scientific as well as economic reasons

Improved Outcome of Allogeneic Transplantation in High-Risk Multiple Myeloma Patients After Nonmyeloablative Conditioning

Evaluation of methods for preparing and thawing cryopreserved CD34+ and CD34− cell lines for use as reagents in flow cytometry of hematopoietic progenitor cells

Mobilization of CD34+ cells in elderly patients (≥ 70 years) with multiple myeloma: influence of age, prior therapy, platelet count and mobilization regimen

Autologous stem cell transplantation followed by consolidation chemotherapy for patients with multiple myeloma

SMALL CHANGES, BIG SAVINGS: IMPACT OF HEMATOPOIETIC PROGENITOR CELLS APHERESIS COLLECTION GOALS ON THE CELL THERAPY LAB

Clonal cytogenetic changes and myeloma relapse after reduced intensity conditioning allogeneic transplantation

Retroviral-mediated gene transfer into CD34-enriched human peripheral blood stem cells

Autotransplantation for advanced lymphoma and Hodgkin's disease followed by post-transplant rituxan/GM-CSF or radiotherapy and consolidation chemotherapy

UC blood infection with clinical strains of Mycobacterium tuberculosis : a novel model

High response rate in refractory and poor-risk multiple myeloma after allotransplantation using a nonmyeloablative conditioning regimen and donor lymphocyte infusions

Mobilization of peripheral blood stem cells in myeloma with either pegfilgrastim or filgrastim following chemotherapy

Suchergebnisse filtern